Frank Douglas has joined The Ewing Marion Kauffman Foundation as a senior fellow in entrepreneurship. He will maintain his position as a partner with PureTech Ventures and as the Chief Scientific Advisor of Bayer Healthcare, AG.
The Ewing Marion Kauffman Foundation today announced that Frank Douglas, Ph.D., M.D., has joined the Foundation as a senior fellow in entrepreneurship. In this capacity, Douglas will leverage his expertise in biotechnology, innovation, academia and venture capital to advise Kauffman leadership on new programming opportunities. In particular, he'll be exploring more effective collaborations amongst the research community, entrepreneurially minded philanthropies in the life-sciences arena, and sources of capital.
Douglas is a partner of PureTech Ventures, a position he will maintain. He will also remain the Chief Scientific Advisor of Bayer Healthcare, AG.
Douglas founded and was the first executive director of the MIT Center for Biomedical Innovation. At MIT, he also was the the Professor of the Practice in the Harvard-MIT Division of Health Sciences and Technology, in the Sloan School of Management, and in the departments of Biology and Biological Engineering.
Formerly, Douglas was executive vice president, chief scientific officer and member of the board of management of Aventis, where he headed drug innovation and approval, with global responsibilities for research, development, and regulatory and marketing support.
“In the world of biotechnology and innovation, Frank Douglas is a stand-out,” said Carl Schramm, the Kauffman Foundation's president and CEO. “His leadership and expertise will be critical as we think about how to help entrepreneurial philanthropists in the life sciences make advances that leverage research funding and ultimately save lives.”
Prior to his positions with Aventis, Douglas was executive vice president of Global Research at Hoechst Marion Roussel and executive vice president of research and development at Marion Merrell Dow. He has been a member of the Scientific Advisory Board of the U.S. Food and Drug Administration, chairman of the executive committee of the Science and Regulatory section of the Pharmaceutical Manufacturers Association (PhRMA), chairman of the board of directors of Alantos, Inc, and member of the board of directors of Gene Logic, Nitromed Inc., and Archemix Inc.
Douglas is the recipient of the 2007 Black History Makers Award and has been honored twice as the Global Pharmaceutical R&D Director of the Year. He has also received the Medal of Honor and an Honorary Professorship from the Johann Wolfgang von Goethe University, Frankfurt, Germany. Frank holds a Ph.D. in Physical Chemistry and M.D. from Cornell University. He did his internship and residency in internal medicine at the Johns Hopkins Medical Institution and a fellowship in neuroendocrinology at the National Institutes of Health.
About the Kauffman Foundation
The Ewing Marion Kauffman Foundation of Kansas City is a private, nonpartisan foundation that works with partners to advance entrepreneurship in America and improve the education of children and youth. The Kauffman Foundation was established in the mid-1960s by the late entrepreneur and philanthropist Ewing Marion Kauffman. Information about the Kauffman Foundation is available at www.kauffman.org .